The US Levodopa market experienced a steady decline in CFR Los Angeles import prices during May 2026, reversing the strong upward momentum recorded in April. The market softened as supply-chain conditions improved and product availability from major Asian exporters increased. In April, Levodopa prices had climbed significantly from March, supported by tighter export availability from India and China, elevated freight charges, war-risk surcharges, and lower inventory levels at key US bonded warehouses. During May, Chinese manufacturers resumed higher cGMP operating rates, while Indian producers eased output restrictions after environmental compliance pressures moderated. These developments improved Levodopa export volumes and shortened lead times, helping US importers replenish inventories more efficiently. Although transpacific freight rates remained above historical averages, logistics conditions improved due to easing port congestion and better container availability. Demand from pharmaceutical manufacturers remained stable, supported by ongoing consumption of Parkinson’s disease therapies. However, reduced emergency Levodopa purchasing activity and stronger competition among Asian exporters pressured prices downward. Analysts expect the market to maintain a similar softening trend in the coming months amid balanced supply conditions and cautious buyer sentiment.
